| Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study |
|
Leukemia |
Aplastic Anemia |
| Immunomodulation With Pomalidomide at Early Lymphocyte Recovery After Induction Chemotherapy in Newly Diagnosed AML and High-Risk MDS |
|
Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Characterization of Myelodysplastic Syndromes (MDS) With T-cell Large Granular Lymphocyte Proliferations (LGL) |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia |
|
Leukemia |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| What causes aplastic anaemia? |
|
Leukemia |
Aplastic Anemia |
| Rethinking clinical trial endpoints in myelodysplastic syndromes. |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria |
|
Leukemia |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study |
|
Leukemia |
Aplastic Anemia |
| Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) |
|
Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
